Clinical Trial Update: Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of visilizumab for moderate to severe inflammatory, nonstricturing Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Visilizumab (visilizumab)

Snippet

Sponsor: Facet Biotech | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED